A protein called SORLA, already known to suppress the amyloid-beta side of Alzheimer's disease, has now been shown to also defend the brain against the toxic tau tangles that cause the other half of the disease's hallmark damage, according to new research published July 17, 2026, in Science Advances by scientists at Sanford Burnham Prebys in La Jolla, California.
When researchers increased SORLA levels in a mouse model of tauopathy, the mice showed significantly reduced tau accumulation, less brain atrophy, and lower activity of disease-related genes in the brain's support cells compared with mice that had normal SORLA levels. The findings position SORLA as a potential therapeutic target for Alzheimer's disease and a broader range of tau-related dementias.
Why This Matters
Alzheimer's disease has two defining molecular pathologies: amyloid plaques, which accumulate outside neurons, and tau tangles, which form inside them. Decades of research have focused on amyloid, producing FDA-approved anti-amyloid therapies like lecanemab (Leqembi) and donanemab (Kisunla). But tau tangles may be more directly tied to neuronal death and cognitive decline, and tau-targeting therapies have lagged significantly behind.
SORLA was already known for its role in suppressing amyloid-beta generation and accumulation, a discovery largely from the lab of Timothy Huang, Ph.D., the study's senior author. "In the last 15 or 20 years, considerable data has come out from our lab and other groups showing that SORLA can suppress one of the hallmarks of Alzheimer's disease: amyloid-beta generation and accumulation," Dr. Huang told EurekAlert. "Very little was known, however, about whether SORLA affected the tau tangles reflected on the other side of the coin in Alzheimer's disease."
The new study answers that question: SORLA also defends against tau pathology. A protein that works against both major disease mechanisms in Alzheimer's is a rare and significant finding.
What We Know So Far
The research team, led by first author Huijie Huang, Ph.D., a staff scientist in the Huang lab, created a new mouse model by crossbreeding mice that produce extra human SORLA protein with mice that develop tau tangles, brain atrophy, and cognitive deficits. This new model allowed direct experiments on SORLA's effects on tau pathology.
The key findings, as described in the Newswise press release and EurekAlert:
An overabundance of SORLA protein protected against multiple biological processes linked to tau tangle formation. Specifically, it reduced hyperphosphorylation of tau, the abnormal addition of too many phosphate groups that causes tau to detach from microtubules and aggregate into tangles. It also reduced the ability of misshapen tau proteins to act as "seeds" that recruit and corrupt neighboring tau molecules, the mechanism by which tau pathology spreads through the brain. Mice with elevated SORLA retained healthier synapses (the communication points between neurons) and better synaptic plasticity (the brain's ability to strengthen or adjust those connections). They also showed less brain atrophy and lower activity of disease-associated genes in glial support cells.
"When you upregulate SORLA, you can suppress the negative effects found in tauopathies," said Huijie Huang. "We found there was less brain atrophy and less tau accumulation, which was very exciting to see."
The study's DOI is 10.1126/sciadv.aed6825 and was published in Science Advances, Volume 12, Issue 29. It was funded by the National Institutes of Health, the National Cancer Institute, and the National Institute on Aging, with no declared competing interests.
Where This Research Stands in the Clinical Pathway
This is a preclinical study in mice. The mouse model of tauopathy used here has proven valuable for studying tau biology, but it does not fully replicate the complexity of human Alzheimer's disease, and many findings from tauopathy mouse models have not translated directly to human clinical outcomes.
The gap between a promising finding in mice and an approved human treatment typically spans 10 to 15 years and involves multiple clinical trial phases. For SORLA, there are additional questions to answer: What is the safest way to increase SORLA levels in the human brain? What are the downstream effects of SORLA upregulation on other brain functions? Does the effect on tau pathology produce clinically meaningful improvements in cognitive function in longer-term animal studies?
The Sanford Burnham Prebys team plans to study how different brain cell types respond to changes in SORLA levels, including experiments placing human neurons and glial cells into mouse brains. These future experiments will build toward understanding whether SORLA's effects can eventually be harnessed therapeutically.
What Doctors and Experts Say
Dr. Huang's team noted that the SORLA upregulation approach worked specifically in the context of tauopathy pathogenesis, affecting multiple upstream steps in tau tangle formation simultaneously. The published paper's conclusion states: "These findings reveal a protective role for SORLA in multiple aspects of tauopathy pathogenesis and highlight its potential as a therapeutic target."
The fact that SORLA addresses both amyloid and tau pathology is significant from a drug development standpoint. Most current Alzheimer's drug candidates target one pathway. A therapy that works on both would theoretically address a broader portion of the disease's biological process.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Preclinical mouse model study (tauopathy transgenic mice crossbred with human SORLA overexpression mice)
- Published in: Science Advances (AAAS), Volume 12, Issue 29; doi: 10.1126/sciadv.aed6825; July 17, 2026
- Institution: Sanford Burnham Prebys, La Jolla, California
- Senior author: Timothy Y. Huang, Ph.D., Assistant Professor, Center for Neurologic Diseases
- First author: Huijie Huang, Ph.D., staff scientist
- ScienceDaily feature date: July 20, 2026 (journal publication date: July 17, 2026)
- Key finding: SORLA overexpression in tauopathy mice reduced tau hyperphosphorylation, tau seeding, brain atrophy, synaptic loss, and disease-associated glial gene activity
- Funding: NIH, National Cancer Institute, National Institute on Aging; no competing interests declared
- What it shows: SORLA acts as a protective factor against multiple aspects of tau pathology in an established mouse model of tauopathy
- What it does not prove: That SORLA upregulation is safe or effective in humans; that increasing SORLA in the human brain is pharmacologically feasible with existing or near-term therapeutic tools
- What readers should know: This is early-stage preclinical research. No clinical trial based on SORLA upregulation has been announced. This does not change current Alzheimer's treatment guidelines or patient care.
Who Should Pay Attention?
This research is most relevant to:
- Patients and families managing an Alzheimer's diagnosis who follow the scientific pipeline for future therapies
- People with a family history of early-onset Alzheimer's or frontotemporal dementia, conditions where tau pathology is particularly central
- Neurologists and dementia researchers who follow tau biology
- Pharmaceutical researchers interested in novel targets for tauopathy drug development
For patients currently on or considering anti-amyloid therapies, this research does not change treatment decisions today.
Symptoms This Research Addresses
SORLA's protective effects, if eventually translated to therapy, would target the biological process underlying these Alzheimer's symptoms:
- Memory loss that disrupts daily activities
- Difficulty with problem-solving or planning
- Confusion with time or place
- Trouble with language, including word-finding problems
- Personality and mood changes driven by neurodegeneration
- Physical changes from brain atrophy in affected regions
Tau pathology, which SORLA appears to suppress in this model, is particularly closely associated with the progressive neuronal death that causes these symptoms to worsen over time.
What You Can Do Now
- Patients and families with Alzheimer's should continue following current evidence-based treatment guidelines. No change in treatment approach is indicated by this research.
- People with a family history of Alzheimer's who want to follow early-stage research developments can track updates at the Alzheimer's Association and the National Institute on Aging .
- Anyone interested in contributing to Alzheimer's research can explore clinical trial participation at ClinicalTrials.gov . Some trials are specifically looking for participants with tau-related pathology or specific genetic risk factors.
- For people interested in following the SORLA research program specifically, Sanford Burnham Prebys maintains a newsroom at news.sanfordburnham.org with updates on the Huang lab's work.
Cost and Access: What Patients Should Know
No SORLA-based treatment is currently available or in clinical trials. Existing FDA-approved Alzheimer's treatments, including anti-amyloid therapies and cholinesterase inhibitors, remain the current standard of care. Patients with concerns about their current treatment plan should consult their neurologist or geriatrician.
What Happens Next
The Sanford Burnham Prebys team will continue experiments to understand how specific brain cell types respond to SORLA changes and whether human neuronal and glial cell responses mirror the mouse findings. If those experiments support the therapeutic hypothesis, the next steps would include identifying drug candidates that can safely increase SORLA levels in the brain and testing them in additional preclinical models before any human trials could begin. MedicalDaily will report on significant advances in this research program.
The Bottom Line
Sanford Burnham Prebys scientists have shown for the first time that the SORLA protein protects the brain not only against amyloid-beta accumulation but also against tau tangle formation, the other defining molecular pathology of Alzheimer's disease. In mice with tauopathy, increasing SORLA levels reduced tau accumulation, brain atrophy, synaptic loss, and disease-related gene activity in support cells. This is preclinical research; clinical application is years away. But the finding identifies a single protein that appears to address both major disease mechanisms in Alzheimer's, making SORLA a significant candidate for further drug development research.
.png?w=600)
